Prof Ingram runs a hidradenitis suppurativa (HS) multidisciplinary team clinic in Cardiff, integrating targeted medical therapy and deroofing surgery. He led the 2018 British Association of Dermatologists (BAD) guideline development group for HS, as well as the Cochrane Review of ‘Interventions for HS’ and is a founding member of HISTORIC, the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration. He is Chief Investigator of H-STRONG, the UK-Irish HS Treatment Registry Study and President of H-SKIN, the HS UK and Ireland Network. He received more than €3.5 million Euros in UK NIHR funding to conduct THESEUS and THESEUS II, observational and randomised controlled studies for HS respectively. Prof Ingram is Treasurer of the CHORD-COUSIN Collaboration (C3) and is co-copyright holder of five instruments measuring HS disease severity, including the Hidradenitis Suppurativa Quality of Life (HiSQOL) instrument.
Prof Ingram trained in medicine at Oxford University, also gaining an MA in Physiological Sciences. He undertook his PhD (Oxford DM) in the field of inflammatory bowel disease and subsequently trained in dermatology in South Wales. During his training he also completed an MSc in Medical Education. He was appointed Consultant Dermatologist in Cardiff in 2013 and was promoted to Clinical Professor by Cardiff University in 2024. Prof Ingram has published 225 papers in peer-reviewed journals and has an h-index of 43 (Google Scholar). He is Dermatology Specialty Lead for Health and Care Research Wales and received a Merit Award (2022-2027) from the UK National Health Service. He is Co-Editor of Rook’s Dermatology Handbook and the author of two UpToDate® chapters on HS. He is also immediate past Editor-in-Chief of the British Journal of Dermatology (BJD), leading the journal from 2019-2024.
